BACKGROUND: No rosacea-specific quality-of-life (QOL) instrument exists. OBJECTIVE: We sought to develop a validated, reliable rosacea-specific instrument. METHODS: From 6 in-depth interviews, we composed 21 rosacea-specific items. These items and Skindex-29 were administered in a validation cohort (n = 59). Internal consistency reliability and reproducibility were measured with Cronbach's coefficient alpha and intraclass correlation coefficient, respectively. Responsiveness was assessed comparing baseline with 4- to 6-month responses. Construct validity was assessed with principal axes factor analyses. Discriminant validity was examined with an additional 38 patients comparing differences in responsiveness between the rosacea-specific QOL instrument and Skindex. RESULTS: Reliability was high (Cronbach's alpha: 0.82-0.97, intraclass correlation coefficient: 0.70-0.95). The rosacea-specific QOL instrument showed preliminary responsiveness for patients with improved disease (P <or= .05). Principal axes factor analyses correlated to hypothesized scales (r = 0.57-0.82). Discriminant validity was illustrated with greater differences in responsiveness using the rosacea-specific QOL instrument (P = .008). LIMITATIONS: Potential selection bias and lack of generalizability was a limitation. CONCLUSIONS: The rosacea-specific QOL instrument, RosaQoL, appears to be a reliable and valid QOL instrument and shows preliminary responsiveness for patients with improving rosacea.
BACKGROUND: No rosacea-specific quality-of-life (QOL) instrument exists. OBJECTIVE: We sought to develop a validated, reliable rosacea-specific instrument. METHODS: From 6 in-depth interviews, we composed 21 rosacea-specific items. These items and Skindex-29 were administered in a validation cohort (n = 59). Internal consistency reliability and reproducibility were measured with Cronbach's coefficient alpha and intraclass correlation coefficient, respectively. Responsiveness was assessed comparing baseline with 4- to 6-month responses. Construct validity was assessed with principal axes factor analyses. Discriminant validity was examined with an additional 38 patients comparing differences in responsiveness between the rosacea-specific QOL instrument and Skindex. RESULTS: Reliability was high (Cronbach's alpha: 0.82-0.97, intraclass correlation coefficient: 0.70-0.95). The rosacea-specific QOL instrument showed preliminary responsiveness for patients with improved disease (P <or= .05). Principal axes factor analyses correlated to hypothesized scales (r = 0.57-0.82). Discriminant validity was illustrated with greater differences in responsiveness using the rosacea-specific QOL instrument (P = .008). LIMITATIONS: Potential selection bias and lack of generalizability was a limitation. CONCLUSIONS: The rosacea-specific QOL instrument, RosaQoL, appears to be a reliable and valid QOL instrument and shows preliminary responsiveness for patients with improving rosacea.
Authors: Joshua A Zeichner; Lawrence F Eichenfield; Steven R Feldman; J Scott Kasteler; Ilia L Ferrusi Journal: J Clin Aesthet Dermatol Date: 2018-02-01
Authors: Esther J van Zuuren; Zbys Fedorowicz; Ben Carter; Mireille M D van der Linden; Lyn Charland Journal: Cochrane Database Syst Rev Date: 2015-04-28
Authors: A M Layton; M Schaller; B Homey; M A Hofmann; A P Bewley; P Lehmann; C Nohlgård; D B Sarwer; N Kerrouche; Y M Ma Journal: J Eur Acad Dermatol Venereol Date: 2015-09-28 Impact factor: 6.166